Gokmen-Polar Y - Search Results

1

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.

Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. Lu M, et al. Cancer Res. 2003 Jun 15;63(12):3425-9. Cancer Res. 2003. PMID: 12810680

2

beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.

Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW Jr. Gökmen-Polar Y, et al. Cancer Res. 2005 Oct 15;65(20):9406-14. doi: 10.1158/0008-5472.CAN-05-0088. Cancer Res. 2005. PMID: 16230404

3

Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.

Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ. Shanmugam R, et al. Prostate. 2006 Oct 1;66(14):1498-511. doi: 10.1002/pros.20482. Prostate. 2006. PMID: 16921510

4

Redefining the target again: chemotherapeutics as vascular disrupting agents?

Gokmen-Polar Y, Miller KD. Gokmen-Polar Y, et al. Cancer Cell. 2008 Sep 9;14(3):195-6. doi: 10.1016/j.ccr.2008.08.006. Cancer Cell. 2008. PMID: 18772108 Free article.

5

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.

Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD. Gökmen-Polar Y, et al. Breast Cancer Res Treat. 2011 Jun;127(2):375-84. doi: 10.1007/s10549-010-1004-y. Epub 2010 Jul 3. Breast Cancer Res Treat. 2011. PMID: 20602165

6

Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.

Gökmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Gökmen-Polar Y, et al. Cancer Res. 2001 Feb 15;61(4):1375-81. Cancer Res. 2001. PMID: 11245437

7

2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells.

Bhati R, Gökmen-Polar Y, Sledge GW Jr, Fan C, Nakshatri H, Ketelsen D, Borchers CH, Dial MJ, Patterson C, Klauber-DeMore N. Bhati R, et al. Cancer Res. 2007 Jan 15;67(2):702-8. doi: 10.1158/0008-5472.CAN-06-3406. Cancer Res. 2007. PMID: 17234781 Free article.

8

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.

Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S. Gökmen-Polar Y, et al. Breast Cancer Res Treat. 2010 Nov;124(2):327-35. doi: 10.1007/s10549-010-0733-2. Epub 2010 Jan 23. Breast Cancer Res Treat. 2010. PMID: 20099025

9

Tumor marker assessment: points to ponder.

Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. Cancer Biol Ther. 2011 Jan 15;11(2):284-6. doi: 10.4161/cbt.11.2.14370. Epub 2011 Jan 15. Cancer Biol Ther. 2011. PMID: 21178400 Free article. No abstract available.

10

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.

Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW Jr. Gökmen-Polar Y, et al. Breast Cancer Res Treat. 2012 Dec;136(3):673-82. doi: 10.1007/s10549-012-2298-8. Epub 2012 Oct 21. Breast Cancer Res Treat. 2012. PMID: 23085766

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters